Living with Multiple Myeloma podcast Multiple Myeloma Ireland

In this podcast, Maire Treasa Ní Cheallaigh chats to sisters Rachel and Laura, whose mum was diagnosed with multiple myeloma in 2016.
Sharing their experiences, they discuss everything from the initial shock of the diagnosis, to the limited  information available for families of myeloma patients, touching on important issues such as patient autonomy, supporting someone close to you with myeloma, and the emotional impact that comes with a loved one receiving a multiple myeloma diagnosis. 
Thanks for listening.
Multiple Myeloma Ireland:
Website
Facebook
Twitter
This podcast has been produced by Fuzion Communications.
 

In this podcast, Episode 1 of the 2nd Series and our second in the Living with Amyloidosis series, Darren Foard and Angelique Smit, nurse experts from the Royal Free Hospital in London, provide an excellent overview of Amyloidosis focussing on disease symptoms, the patient's journey and diagnostic investigations to confirm AL Amyloidosis. 
They discuss their role in assisting patient navigate their diagnosis and outline the referral pathway for Irish patients for further investigation at the National Amyloidosis Centre at the Royal Free Hospital in London. 
Amyloidosis management requires a multidisciplinary approach and Darren and Angelique outline the collaboration which occurs between nursing and medical staff to coordinate the patient's diagnosis and management and the critical role each team member plays in supporting patients.
Finally they discuss the opportunity for patients unfit to travel to the UK for assessment to be discussed with Amyloidosis experts at the Royal Free Hospital.
We hope you find this episode useful and informative.
 
Multiple Myeloma Ireland:
Website
Facebook
Twitter
This podcast has been produced by Fuzion Communications.
 

In this podcast Prof O’ Dwyer provides an excellent overview of effective treatments in Multiple Myeloma.
He has seen the development of many new drugs leading to improved survival in MM patients over his career and he discusses these in detail.
He highlights the role of the immune system and the development of immunomodulatory agents to treat Myeloma. Prof O’Dwyer explains the treatment options at diagnosis and the decision making process regarding treatments at relapse.
Drugs discussed include Thalidomide, Lenalidomide and Pomalidomide , Bortezomib, Carfilzomib, Bi Specific antibodies drugs and Car T Cells.
Fitness rather than numerical age is more important and treatments are individualised. Early recognition and treatment of side effects is critical. Finally Prof O’Dwyer also discusses the role of clinical trials in treating MM.
 
Multiple Myeloma Ireland:
Website
Facebook
Twitter
This podcast has been produced by Fuzion Communications.
 

In this podcast Dr John Quinn explains how AL Amyloidosis, a rare illness which is not fully understood, can often be tricky to diagnose.  
Early diagnosis, however, is key to minimise organ damage and treatments have improved over the past 10 years with high response rates piggybacking off myeloma treatments. There is no typical Amyloidosis patient and many may have been feeling unwell for 9-12 months before a diagnosis is made.
Symptoms of Amyloidosis vary among patients and include generalised tiredness, weight loss, feeling lightheaded, numbness or a tingling feeling in hands or feet, easy bruising, purple spots or bruising around eyes and swelling in the abdomen, legs ankles or feet. Patients may also experience shortness of breath, reduced appetite and altered bowel habits.
In Amyloidosis, the recycling of proteins becomes a problem and light chains are produced which build up in organs around the body. The protein hides in the heart, liver, kidneys gut, skin or nervous system and causes organ damage.
Specialist investigations including blood tests, chest x-ray, tracing of heart (ECG), tests for protein in the urine, biopsy of organs affected if possible are completed. A SAP scan a specific scan is used to determine where amyloid deposits are in the body.Patients supported by the HSE travel to the Amyloidosis centre at the Royal Free Hospital London for this test.
As Amyloidosis is a multi-system disease, Multidisciplinary team collaboration is critical to manage patients. However, according to Dr Quinn the outlook for Amyloidosis patients has never been better with significant improvement in survival rates.
Treatment involves chemotherapy, steroids and targeted therapies including antibody therapy. Clinical trials for patients with light amyloidosis and cardiac involvement will begin soon at Beaumont Hospital. This is the first podcast on Amyloidosis. We will soon share others from patients and nurse specialists.
A huge thank you to Dr. John Quinn for his time.
This show is brought to you by Multiple Myeloma Ireland:
Website
Facebook
Twitter
This podcast has been produced by Fuzion Communications.
 

In this final podcast of the series, Journalist, ex-Irish Times correspondent, Kerryman, and Multiple Myeloma patient Michael O’Regan discusses his experience of living with the condition.
Michael's chat with Maire Treasa was recorded as part of the podcast series launch. In this engaging and honest account of Michael's personal story he outlines his diagnosis and treatment journey, which was complicated by the fact that it was his second cancer diagnosis.
His first being a tumour on his leg back in 2018, which could have delayed his multiple myeloma diagnosis. He describes how he had some “classic” symptoms of the disease such as chronic back pain, however  he was attributing these to his recovery from surgery and radiation for the leg tumour.
Michael had felt unwell for some time and knew something was wrong. A routine test in 2019 finally identified multiple myeloma, which Michael describes as his “second spin on the cancer merry-go round”. Along with monthly intravenous medication, Michael is now also on kidney dialysis three times a week.
Michael, openly gives his personal experience of how he has coped mentally with his diagnosis,  “I’d like to say I dealt with this with bravery and courage and acceptance - I didn’t. I never lapsed into self-pity but I did rage against a second cancer diagnosis”.
He admits that, like many others diagnosed with multiple myeloma, the disease was not on his radar, and he knew very little about it when diagnosed. He is also honest about how he coped. For someone whose career is based on communication, he admitted that it took a while for him to talk about having cancer.
He describes how he found opening up on a personal level difficult, but with the help and support of psychology and excellent healthcare professionals once he decided he would be open about it, it gave him a certain “freedom”. Michael outlines how he went through depression, exhaustion, the physical and the mental side of the condition and its treatment.
He describes his journey through lost and adjustments to now living a “full life”. He describes how it is important to find the right way for each individual to cope. He talks about how the commitment of healthcare professionals and reading other peoples stories has help him, along with volunteer groups. Finally, Michael describes how “cancer can be dealt with” and the excellent treatment available to Irish patients.
Multiple Myeloma Ireland:
Website
Facebook
Twitter
This podcast has been produced by Fuzion Communications.

In this podcast Professor Siobhan Glavey, provides an update of the rapid developments in managing Multiple Myeloma.
Professor Glavey explains how the future has never been more hopeful as significant improvement in treatment options has resulted in unprecedented progression free survival (PFS).
Today not only are patients living longer, they have a healthier quality of life. Professor Glavey explains the many variables in managing myeloma and the importance of a personalised approach, using the right drugs with the right patient. In her discussion with Maire Treasa she outlines the many factors that influence the decision to treat a patient including patient related factors and treatment related factors.
She describes the findings from clinical trials and gives an overview of the results presented at the American Society of Haematology (ASH) annual conference. She explains how for patients who are transplant eligible the results at ASH confirm transplant is here to stay, as 3 year PFS was better in those who received a transplant.
In addition, Prof Glavey explains for transplant ineligible patients, effective treatments have also resulted in increased PFS. She explains how 3 drug combinations is standard today in Ireland for the majority of patients. However, in the future 4 drug  combinations will be used with each drug having a different mechanism of action to treat the disease. No one size of treatment fits all and it is important to consider different drugs or different drug doses when treating individual patients and managing side effects.
She explains there is no wonder drug, she highlights the importance of availability of clinical trials for our patients and the importance of continually pushing the boundaries. Prof Glavey outlines how we have a good repertoire of drugs with many more still to come including antibody drug conjugates. The future is brighter as we work together to treat Multiple Myeloma.
Multiple Myeloma Ireland:
Website
Facebook
Twitter
This podcast has been produced by Fuzion Communications.